中国基层医药
中國基層醫藥
중국기층의약
CHINESE JOURNAL OF PRIMARY MEDICINE AND PHARMACY
2012年
11期
1605-1606
,共2页
陈利明%席兴华%杨仕庆%陈景成
陳利明%席興華%楊仕慶%陳景成
진리명%석흥화%양사경%진경성
贝伐珠单抗%翼状胬肉%干细胞移植%复发
貝伐珠單抗%翼狀胬肉%榦細胞移植%複髮
패벌주단항%익상노육%간세포이식%복발
Bevacizumab%Pterygium%Stem cell transplantation%Recurrence
目的 观察贝伐珠单抗对翼状胬肉切除联合角膜缘干细胞移植术后复发的影响.方法 回顾性分析收治的单纯翼状胬肉75例(99眼)患者的治疗资料,根据用药不同,分为A组,即采用在翼状胬肉切除联合角膜缘干细胞移植术的基础上加用贝伐珠单抗;B组,在翼状胬肉切除联合角膜缘干细胞移植术基础上加用丝裂霉素C;C组,单纯采用翼状胬肉切除联合角膜缘干细胞移植术.术后随访3个月,比较治疗效果、复发情况.结果 A组复发4例(12.1%),B组复发5例(15.2%),C组复发15例(45.5%);A组与B组复发率差异无统计学意义(x2 =2.117,P>0.05),B组与C组复发率差异有统计学意义(x2=3.930,P<0.05),A组与C组复发率差异有统计学意义(x2 =4.455,P<0.05);三组复发率差异有统计学意义(F=12.267,P<0.05);所有患者术后1周内有不同程度的眼痛、畏光、流泪,1周后消失;B组有2例术后发现角巩膜缘出现浅层巩膜坏死、浅层点状角膜炎.A组平均5.9d拆线,B组为7.0d拆线,C组为7.5d拆线.结论 贝伐珠单抗能有效减少翼状胬肉切除联合角膜缘干细胞移植术后复发,且并发症少.
目的 觀察貝伐珠單抗對翼狀胬肉切除聯閤角膜緣榦細胞移植術後複髮的影響.方法 迴顧性分析收治的單純翼狀胬肉75例(99眼)患者的治療資料,根據用藥不同,分為A組,即採用在翼狀胬肉切除聯閤角膜緣榦細胞移植術的基礎上加用貝伐珠單抗;B組,在翼狀胬肉切除聯閤角膜緣榦細胞移植術基礎上加用絲裂黴素C;C組,單純採用翼狀胬肉切除聯閤角膜緣榦細胞移植術.術後隨訪3箇月,比較治療效果、複髮情況.結果 A組複髮4例(12.1%),B組複髮5例(15.2%),C組複髮15例(45.5%);A組與B組複髮率差異無統計學意義(x2 =2.117,P>0.05),B組與C組複髮率差異有統計學意義(x2=3.930,P<0.05),A組與C組複髮率差異有統計學意義(x2 =4.455,P<0.05);三組複髮率差異有統計學意義(F=12.267,P<0.05);所有患者術後1週內有不同程度的眼痛、畏光、流淚,1週後消失;B組有2例術後髮現角鞏膜緣齣現淺層鞏膜壞死、淺層點狀角膜炎.A組平均5.9d拆線,B組為7.0d拆線,C組為7.5d拆線.結論 貝伐珠單抗能有效減少翼狀胬肉切除聯閤角膜緣榦細胞移植術後複髮,且併髮癥少.
목적 관찰패벌주단항대익상노육절제연합각막연간세포이식술후복발적영향.방법 회고성분석수치적단순익상노육75례(99안)환자적치료자료,근거용약불동,분위A조,즉채용재익상노육절제연합각막연간세포이식술적기출상가용패벌주단항;B조,재익상노육절제연합각막연간세포이식술기출상가용사렬매소C;C조,단순채용익상노육절제연합각막연간세포이식술.술후수방3개월,비교치료효과、복발정황.결과 A조복발4례(12.1%),B조복발5례(15.2%),C조복발15례(45.5%);A조여B조복발솔차이무통계학의의(x2 =2.117,P>0.05),B조여C조복발솔차이유통계학의의(x2=3.930,P<0.05),A조여C조복발솔차이유통계학의의(x2 =4.455,P<0.05);삼조복발솔차이유통계학의의(F=12.267,P<0.05);소유환자술후1주내유불동정도적안통、외광、류루,1주후소실;B조유2례술후발현각공막연출현천층공막배사、천층점상각막염.A조평균5.9d탁선,B조위7.0d탁선,C조위7.5d탁선.결론 패벌주단항능유효감소익상노육절제연합각막연간세포이식술후복발,차병발증소.
Objective To explore the clinical effents of bevacizumab on the recrudescence of the limbal corneal epithelial cell auto-graft transplantation in treating patients with pterygium.Methods The clinical data of 75 cases(99 eyes) with pterygium were retraspectively reviewed,and they were divided into 3 groups by different conservative treatment.A group:the limbal corneal epithelial cell auto-graft transplantation combined with bevacizumab.B group:the limbal corneal epithelial cell auto-graft transplantation combined with MMC.C group:the limbal corneal epithelial cell auto-graft transplantation.After follow-up for 3 months,the curative effect and recurrence were compared between the two groups.Results The recurrence of three groups was significantly different( x2 =12.267,P < 0.05 ).The reccurrence rate of A,B,C group were 12.1%,15.2%,45.5%.The recurrence rate of A group and B group wasn't significantly different(x2 =2.117,P >0.05).The recurrence rate of B group and C group wasn't statistically different( x2 --3.930,P < 0.05 ).The recurrence rate of A group and C group was significantly different( x2 =4.155,P < 0.05 ).After 1 week,all patients had different degrees of eye pain,photophobia or tearing,and disappeared after 1 week;2 patients in group B found that limbal shallow scleral necrosis,superficial punctate keratitis.The average time of removal of stitches in group A was 5.9d,group B was 7.0d and group C was 7.5d.Conclusion Bevacizumab could obviously reduce the recrudescence of the limbal corneal epithelial cell auto-graft transplantation in treating patients with pterygium.It was safe with less complications and good prognosis.It was worthy for being widely used in treatment of pterygium.